Does BPC-157 work? Three human studies, all of them pilots

Does BPC-157 work? The human evidence is too thin to answer. A 2025 review that set out to catalogue the entire literature found only three pilot studies that had ever given BPC-157 to people: one injecting it into painful knees, one in interstitial cystitis (a long-term bladder pain condition), and one checking whether an intravenous infusion was safe [1].

The knee study is the one that speaks to what most people want the peptide for. It is a case series, meaning a report on patients who were all treated, with nobody left untreated for comparison. A 2026 review in a sports medicine journal describes it as reporting less pain after injections into the joint itself, while noting significant methodological flaws and the absence of a control group, which is why it cannot settle anything [11].

The safety record is thin in the same way. The intravenous study enrolled two adults, a man of 58 and a woman of 68, both of whom had been given intravenous BPC-157 before. They received one infusion on each of two days, the second twice the size of the first, and afterwards their blood showed no change in markers of heart, liver, kidney or thyroid function, and no side effects were reported [14]. Two people over three days cannot establish that something is safe.

Almost everything else is animal work, and it is broadly positive. Reviews of the rodent literature report faster healing in tendon, ligament, skeletal muscle, bone and gut tissue, with new blood vessels forming and more collagen laid down [7][9]. In one 2015 experiment, BPC-157 applied to alkali burns on rats closed the wounds faster than no treatment, with denser collagen and more new tissue by day 18 [10].

What no study answers is how anyone should use it. The 2026 sports medicine review states that the indications, dose, frequency and duration of treatment all remain unknown [11]. Capsules, injections into a specific joint and infusions are all sold, and the research does not establish which of them, if any, does anything in a person. A 2026 review of regenerative peptides, BPC-157 among them, notes that most of the compounds it covers are unapproved by the US Food and Drug Administration [13], and reviews of BPC-157 specifically point to regulatory restrictions and inconsistent preparation standards in what reaches buyers [1][9].

The proposed mechanism is blood supply. BPC-157 is a synthetic chain of 15 amino acids, first identified in gastric juice, and in laboratory models it switches on angiogenesis, the growth of new blood vessels. It appears to do this partly through a receptor called VEGFR2, which cells use to sense the signal to build vessels, and partly by raising nitric oxide, a molecule that widens vessels and increases flow [1].

That would matter most in tissue with a poor blood supply. Tendons and ligaments receive far less blood than muscle, which is one reason they heal slowly, and the rodent studies report the clearest effects in exactly those places: tendons, and the junctions where muscle meets tendon [1][7].

Alongside the vessels, the peptide seems to activate fibroblasts, the cells that lay down collagen, the fibrous protein that gives tendon and skin their strength. It also appears to quieten inflammatory signalling and to alter pain signalling in the nerves [9]. In cell and animal experiments the effect runs through ERK1/2, a signalling pathway cells use to decide whether to grow, move or build new vessels [10].

All of that describes what the compound does to cells and to rats. The trials that would show whether any of it carries over to a person have not been run, which is the point a 2026 review of peptides in orthopaedics lands on: the preclinical work looks promising and the clinical trials do not yet exist [2].

The evidence is broad in animals and nearly absent in humans.

Who the research does not cover:

• anyone with a torn tendon or muscle, the most common reason people buy it, since no controlled trial has tested BPC-157 on a sports injury in a person [1][11]
• people taking it by mouth or injecting themselves, because the human studies used an infusion or an injection into a joint [1][14]
• anyone hoping for an effect on ageing, as none of this research measured lifespan or any age-related outcome
• long-term users, because the human work ran for days, not months [14]

The animal literature has a narrow base of its own. A 2019 review found that most of the work sits in small rodent models, and that over two decades only a handful of research groups had studied the peptide in depth [7]. A finding that keeps coming back from the same few laboratories counts for less than one many independent groups have reproduced.

No reported side effects is not the same as demonstrated safety. Nobody in the three human pilot studies reported a serious problem [1], but the one whose size is published involved two people [14], and side effects that are uncommon would not surface in a group that small. Because supply also reaches buyers through unregulated channels where preparation standards vary [1][9], the safety of a particular vial is a separate question from the safety of the compound. Whether to use a prescribed peptide is a decision for a doctor and patient together.

Peptide therapy is one of the most widely sold services in longevity medicine: 38 of the clinics in the Longevinsights directory list it, across 25 cities. BPC-157 sits in that category alongside growth hormone peptides such as sermorelin and ipamorelin, which act on an entirely different pathway [2].

These are prescribed compounds rather than shelf products, so a first appointment is a consultation rather than a treatment. A clinician takes a history and decides what, if anything, to prescribe. Given that the reviews put the dose, route, frequency and duration in the unknown column [11], the questions worth asking are which human studies the clinic is relying on, what it expects the peptide to do, and whether what it supplies is an approved medicine [13].